p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer

Document Type

Article

Publication Date

6-3-2025

Publication Title

Cancer epidemiology, biomarkers & prevention

Abstract

BACKGROUND: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited.

METHODS: In a case-control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC.

RESULTS: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38-3.54).

CONCLUSIONS: p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS.

IMPACT: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.

Medical Subject Headings

Humans; Female; Cyclooxygenase 2; Breast Neoplasms; Ki-67 Antigen; Case-Control Studies; Carcinoma, Intraductal, Noninfiltrating; Middle Aged; Cyclin-Dependent Kinase Inhibitor p16; Aged; Biomarkers, Tumor; Risk Factors; Adult; Neoplasm Invasiveness

PubMed ID

40227115

ePublication

ePub ahead of print

Volume

34

Issue

6

First Page

1036

Last Page

1039

Find It @ Sladen

Share

COinS